Alkem Laboratories Reports Mixed Q1 FY27 Results; Brokers Adjust Earnings Estimates
Alkem Laboratories reported mixed first-quarter FY27 results, with Nomura noting revenue, EBITDA, and PAT below estimates due to slower domestic growth and higher operating costs, while Motilal Oswal highlighted in-line revenue and EBITDA with a PAT beat driven by improved segment mix and operating leverage. Both brokers raised earnings estimates, factoring in growth from new acquisitions and chronic therapies, despite challenges in trade generics and the CDMO business. Nomura retained a 'Buy' rating, and Motilal Oswal assigned a target price of Rs 5,770.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (56/100). Lens Score 35/100.
Outlets measured: moneycontrol, moneycontrol. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (55–58/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
moneycontrol broke this story on 17 Aug, 05:44 am. Other outlets followed.